ガンマセクレターゼ(EC3.4.23)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Gamma Secretase (EC 3.4.23.) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0448
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:78
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Gamma Secretase (EC 3.4.23.) – Pipeline Review, H2 2019
Summary

Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma Secretase (EC 3.4.23.) – Pipeline Review, H2 2019, outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gamma Secretase (EC 3.4.23.) – Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer’s disease patients. Gamma secretase is also critical in the related processing of the Notch protein.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 11 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Cardiovascular and Non Malignant Disorders which include indications Alzheimer’s Disease, Adenoid Cystic Carcinoma (ACC), Hearing Disorders, Lymphoblastic Lymphoma, Metastatic Breast Cancer, Soft Tissue Sarcoma, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), T-Cell Lymphomas, Acute Sensorineural Hearing Loss, Benign Tumor, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Colorectal Cancer, Congestive Heart Failure (Heart Failure), Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hematological Tumor, Leiomyosarcoma, Leukemia, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Natural Killer Cell Lymphomas, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor, Squamous Non-Small Cell Lung Cancer, T-Cell Leukemia and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
- The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gamma Secretase (EC 3.4.23.) – Overview
Gamma Secretase (EC 3.4.23.) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gamma Secretase (EC 3.4.23.) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gamma Secretase (EC 3.4.23.) – Companies Involved in Therapeutics Development
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Gamma Secretase (EC 3.4.23.) – Drug Profiles
ACD-679 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACD-680 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AL-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986133 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenigacestat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EF-005 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PSEN1 for Heart Failure – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSI-34 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-226A1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3056480 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGP-555 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nirogacestat hydrobromide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit PSEN1 for Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PIPE-505 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Gamma Secretase for Hearing Loss – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PSEN1 for Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate Gamma Secretase for Alzheimer’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma Secretase (EC 3.4.23.) – Dormant Products
Gamma Secretase (EC 3.4.23.) – Discontinued Products
Gamma Secretase (EC 3.4.23.) – Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline’s BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting
Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO
Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe
Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)
Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug
May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer
May 20, 2019: SpringWorks Therapeutics announces initiation of Phase 3 trial (DeFi) of nirogacestat in adult patients with desmoid tumors
May 13, 2019: FDA grants Orphan Drug Designation to Ayala’s AL101 for potential treatment of adenoid cystic carcinoma (ACC)
Mar 07, 2019: New drug could restore hearing in the deaf
Mar 06, 2019: Ayala Pharmaceuticals to present preclinical data at AACR for AL101, a pan-notch inhibitor being evaluated for adenoid cystic carcinoma
Feb 05, 2019: Audion Therapeutics and REGAIN consortium announce positive phase I results in patients with sensorineural hearing loss
Dec 17, 2018: Ayala Pharmaceuticals announces first patient enrolled in phase 2 study of lead product candidate AL101 for Adenoid Cystic Carcinoma with notch activated mutations
Nov 07, 2018: SpringWorks Therapeutics receives FDA fast track designation for Nirogacestat for the treatment of adult patients with desmoid tumors
Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers
Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AlzeCure Pharma AB, H2 2019
Pipeline by Astellas Pharma Inc, H2 2019
Pipeline by Audion Therapeutics BV, H2 2019
Pipeline by Ayala Pharmaceuticals Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Everfront Biotech Inc, H2 2019
Pipeline by Lipopharma Therapeutics SL, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2019
Pipeline by Pharchoice Therapeutics Inc, H2 2019
Pipeline by Pipeline Therapeutics Inc, H2 2019
Pipeline by SpringWorks Therapeutics Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

【掲載企業】

AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Bristol-Myers Squibb Co
Cotinga Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
Lipopharma Therapeutics SL
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Takeda Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ガンマセクレターゼ(EC3.4.23)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆